# Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

> **NCT02899104** · — · COMPLETED · sponsor: **Bayer** · enrollment: 200 (actual)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **DRUG:** Xofigo (Radium-223 dichloride, BAY88-8223)

## Key facts

- **NCT ID:** NCT02899104
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-15
- **Primary completion:** 2019-03-31
- **Final completion:** 2019-03-31
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2020-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02899104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02899104, "Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02899104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*